Melasma

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

DermBiont
DermBiontMA - Boston
1 program
1
SM-030 gel 0.64%Phase 21 trial
Active Trials
NCT06454747Recruiting138Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
DermBiontSM-030 gel 0.64%

Clinical Trials (1)

Total enrollment: 138 patients across 1 trials

NCT06454747DermBiontSM-030 gel 0.64%

Randomized Study Using SM-030 Gel for Adults With Melasma

Start: Jun 2024Est. completion: Oct 2025138 patients
Phase 2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 138 patients
1 companies competing in this space